2025-12-24 - Analysis Report
Okay, here's a report based on the provided data for Intuitive Surgical Inc. (ISRG):

**1. Return Rate vs. S&P 500 (VOO)**

*   **Ticker:** ISRG
*   **Company:** Intuitive Surgical Inc.
*   **Overview:**  Intuitive Surgical designs, manufactures, and markets robotic surgical systems.
*   **ISRG Cumulative Return:** 111.57%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:**
    *   Current: 10.7
    *   Range (Min: -37.8, Max: 98.9)
    *   Relative Divergence: 35.5

**Analysis:** ISRG has outperformed the S&P 500 over the period considered, with a current cumulative return approximately 10.7 percentage points higher. The relative divergence of 35.5 suggests that the current divergence is towards the lower end of the historical divergence range between ISRG and the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 77.6% | 40.0% | -0.1 | 44.0 |
| 2016-2018  | 64.0% | 72.2% | 49.0% | -0.0 | 57.7 |
| 2017-2019  | 54.0% | 72.2% | 31.0% | 0.2 | 71.2 |
| 2018-2020  | -6.0% | 80.4% | -29.0% | 0.3 | 98.6 |
| 2019-2021  | 29.0% | 80.4% | -18.0% | 0.6 | 129.9 |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2 | 95.9 |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7 | 122.0 |
| 2022-2024  | 36.0% | 77.5% | 15.0% | 1.7 | 188.7 |
| 2023-2025  | 74.0% | 72.7% | 8.0% | 0.8 | 207.0 |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate fluctuates significantly.  High growth periods are followed by periods of decline.  The most recent period (2023-2025) shows a strong rebound.
*   **MDD:** The Maximum Drawdown is consistently high, indicating substantial potential for losses during downturns.
*   **Alpha:** Alpha is largely negative in recent years, especially from 2018-2023. The last two period shows positive alpha. This suggests underperformance relative to the risk-free rate plus the market risk premium in recent years.
*   **Beta:** Beta has been trending upwards, reaching 1.7 in 2021-2024, but dropping back down to 0.8 in 2023-2025. This indicates that ISRG's price fluctuations have become more correlated with, and amplified compared to, the market's movements.
*   **Cap(B):** Market capitalization has grown substantially over the analyzed periods.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 572.47
*   **Last Market Data:**
    *   Price: 577.34
    *   Previous Close: 579.83
    *   Change: -0.43
*   **5-day SMA:** 561.06
*   **20-day SMA:** 564.08
*   **60-day SMA:** 522.79

**Analysis:**

The current price is slightly below the last market close. The 5-day and 20-day SMAs are close to each other, suggesting a relatively stable short-term trend. However, the price is significantly above the 60-day SMA, indicating an overall upward trend in the medium term.

**3. RSI, PPO, and Expected Return**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 52.71 (Neutral)
*   **PPO:** -0.34 (Slightly Oversold)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change:** 8.0 (+) (Short-term Increase)
*   **Expected Return:** 23.9% (Long-term)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI of 52.71 is considered neutral, indicating neither overbought nor oversold conditions.
*   The slightly negative PPO suggests the stock may be slightly oversold in the short term, which can sometimes precede a price increase.
*   The recent increase in relative divergence (+8.0) indicates a recent period of outperformance compared to the S&P 500.
*   The expected return of 23.9% is a significant potential upside if held long-term.

**4. Recent News & Significant Events**

*   **Positive Sentiment:** Multiple articles suggest a positive outlook for Intuitive Surgical.  One article questions if ISRG is a buy now, implying it's a stock worth considering. OFI Invest Asset Management purchased shares, indicating institutional confidence.
*   **Comparative Analysis:** The Motley Fool compares ISRG to Novo Nordisk, suggesting a decision point for investors.
*   **Valuation & Outlook:**  Trefis highlights high margins and a potential discount, while ts2.tech provides an updated outlook including analyst forecasts.
*   **Risk Assessment:** Forbes discusses both the buy opportunity and potential risks.

**Analysis:**  Recent news coverage is generally positive, focusing on potential buy opportunities, high margins, and a strong outlook.  However, the Forbes article acknowledges potential risks. The articles suggest that analysts are actively covering and updating their forecasts for ISRG.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.06)
*   **Opinions:** 29
*   **Target Price:**
    *   Average: 599.60
    *   High: 700.00
    *   Low: 378.00
*   **Recent Rating Changes:** No changes reported

**Analysis:** The analyst consensus is a "Buy" with a significant number of opinions contributing to that consensus. The average target price suggests a potential upside from the current price. The absence of recent rating changes could indicate a period of stability in analyst sentiment or a lack of recent data updates. The wide range in target prices (378.00 - 700.00) also suggest that there is still a divide for what the future price will be.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 1.98 | 2.51 B$    |
| 2025-07-23 | 1.84 | 2.44 B$    |
| 2025-04-23 | 1.95 | 2.25 B$    |
| 2024-10-18 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |

**Analysis:**

*   **Growth:**  Both EPS (Earnings Per Share) and revenue have generally been increasing over the last year. EPS increased from 1.59 to 1.98, and revenue increased from 2.04B$ to 2.51B$.
*   **Consistency:** The EPS and revenue growth are relatively consistent, indicating a stable business trajectory.

**6. Financial Information (Revenue/Profitability & Capital/Profitability)**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $2.51B   | 66.36%        |
| 2025-06-30 | $2.44B   | 66.31%        |
| 2025-03-31 | $2.25B   | 64.69%        |
| 2024-12-31 | $2.41B   | 68.04%        |
| 2024-09-30 | $2.04B   | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
|--------------|-------------|---------|
| 2025-09-30 | $16.93B    | 4.16%   |
| 2025-06-30 | $17.85B    | 3.69%   |
| 2025-03-31 | $17.11B    | 4.08%   |
| 2024-12-31 | $16.43B    | 4.17%   |
| 2024-09-30 | $15.58B    | 3.63%   |

**Analysis:**

*   **Revenue & Profitability:** Revenue is increasing, and profit margins remain very high (above 64%). This demonstrates a strong ability to generate profit from sales.
*   **Capital & Profitability:** Equity is increasing gradually. ROE (Return on Equity) fluctuates but is relatively stable, indicating consistent profitability relative to shareholder equity.

**7. Comprehensive Analysis**

Intuitive Surgical (ISRG) presents a mixed but generally positive picture:

*   **Outperformance:** ISRG has outperformed the S&P 500.
*   **Growth & Profitability:** The company exhibits strong revenue and earnings growth with high profit margins.
*   **Analyst Sentiment:** Analyst consensus is a "Buy," and target prices suggest potential upside.
*   **Technical Indicators:** Technical indicators offer a mixed signal, with the RSI neutral, the PPO slightly oversold, and recent divergence showing short-term outperformance.
*   **Risk Considerations:** The high MDD in the historical data, recent negative alpha, and fluctuating Beta suggest that the stock has a relatively high risk profile and can be more volatile than the market.
*   **Market Risk Indicator:** The MRI suggest a medium investment recommendation.

**Overall Recommendation:**

Based on the provided information, ISRG appears to be a potentially attractive investment, particularly for long-term investors willing to accept higher volatility. The positive analyst sentiment, strong financial performance, and potential for future growth support a cautiously optimistic outlook. However, the high MDD and recent performance fluctuations warrant careful consideration of individual risk tolerance and investment goals. It would be wise to do further research to get a better understanding of the stock and its position in its sector.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.